| Gilead Sciences Places $120M Bet on a Jounce Therapeutics Cancer Drug | Frank Vinluan | 09/01/20 | San Francisco |
| Xilio Unveils New Name, $100M to Bring Targeted Cancer Drugs to Clinic | Frank Vinluan | 03/02/20 | Boston |
| ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More | Alex Lash | 06/05/19 | National |
| Immunotherapy Is Now Here For Breast Cancer. What Are Its Prospects? | Ben Fidler | 05/29/19 | National |
| Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More | Frank Vinluan | 04/26/19 | National |
| In Another Lung Cancer Setback, Bristol Yanks FDA App For Drug Combo | Ben Fidler | 01/24/19 | New York |
| Bio Roundup: Aimmune Drama, Shutdown Blues, Perlmutter Talks Cancer | Ben Fidler | 01/18/19 | National |
| ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front | Alex Lash | 10/23/18 | National |
| FDA’s Latest Cancer Approval Underscores Immunotherapy Nobel Prize | Alex Lash | 10/01/18 | National |
| Bristol Nabs Immunotherapy’s First FDA Nod for Small Cell Lung Cancer | Ben Fidler | 08/17/18 | New York |
| IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down | Ben Fidler | 05/31/18 | National |
| Ahead of ASCO, Merck Touts Another Win for Lung Cancer Drug Combo | Ben Fidler | 05/23/18 | New York |
| Bio Roundup: Hope for Lungs, Bradner’s Complaint, FDA Nods & More | Alex Lash | 04/20/18 | National |
| With New Data, Drug Combos, Lung Cancer Experts Scramble to Keep Pace | Ben Fidler | 04/11/18 | National |
| Bio Roundup: CMS Backs Cancer Tests, Right to Try Passes, AbbVie Sinks | Ben Fidler | 03/23/18 | National |
| Bio Roundup: Lung Cancer Questions, Migraine Races, HIV Battle & More | Ben Fidler | 02/09/18 | National |
| Bristol-Myers Immune Drug Combo Hits Early Mark in Lung Cancer Study | Frank Vinluan | 02/05/18 | New York |
| BioCryst, Idera Plan Merger in Tie-Up of Rare Disease Drug Developers | Frank Vinluan | 01/22/18 | Raleigh Durham |
| Merck Is Latest to Tout Success as Lung Cancer Drug Combos Plow Forward | Ben Fidler | 01/16/18 | New York |
| 15 For ’18: Key Clinical Data to Watch For Next Year (Part 1) | Ben Fidler | 12/04/17 | National |
| Five Prime Shares Dive on Latest Hiccup For Cancer Immunotherapy Combos | Frank Vinluan | 11/07/17 | San Francisco |
| Bio Roundup: RNAi Drama, Immunotherapy Data, Lasker Winners & More | Ben Fidler | 09/08/17 | National |
| Bio Roundup: Frazier v. Trump, Data Dumps, New York Steps & More | Ben Fidler | 08/18/17 | National |
| Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer | Ben Fidler | 08/16/17 | New York |
| On ASCO’s Eve, Experts Fret Over Backlash to Cancer Combo Frenzy | Ben Fidler | 05/30/17 | National |
| First Trial Underway, CytomX Gets $200M More In Expanded Bristol Pact | Ben Fidler | 03/20/17 | San Francisco |
| Bio Roundup: Clinical Shirkers, AMD Worriers, ASH Fallers & More | Alex Lash | 11/04/16 | National |
| In Immuno-Oncology’s Latest Win, FDA OK’s Genentech Drug | Alex Lash | 05/18/16 | San Francisco |
| Cancer Vaccines Back in Vogue as VCs Put $102M Into Gritstone Oncology | Ben Fidler | 10/20/15 | San Francisco |
| East Coast Biotech Roundup: Forum, Neon, Sarepta, Accelerator & More | Ben Fidler | 10/02/15 | Boston |
